Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Maes

Showing results (31-40 of 723) with videos related to

Pageof 73
Sort By:
CNS & Neurological Disorders Drug Targets|October 1, 2020
Biomarker Validation of a New Case Definition of Menstrual Cycle-Associated Syndrome (MCAS) Opinion PaperChutima Roomruangwong, Michael Maes
Current Pharmaceutical Design|December 31, 2014
Overlapping the Tryptophan Catabolite (TRYCAT) and Melatoninergic Pathways in Alzheimer's DiseaseMichael Maes, George Anderson
Frontiers in Psychiatry|July 5, 2021
False Dogmas in Schizophrenia Research: Toward the Reification of Pathway Phenotypes and Pathway ClassesMichael Maes, George Anderson
The International Journal of Neuropsychopharmacology|December 6, 2002
Effects of antidepressants on the production of cytokinesGunter Kenis, Michael Maes
Current Pharmaceutical Design|November 5, 2013
Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: treatment implicationsGeorge Anderson, Michael Maes
Journal of Affective Disorders|December 16, 2003
Partial posttraumatic stress disorder revisitedJacques Mylle, Michael Maes
Psychiatry Research|February 28, 2012
Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathwayMichael Maes, Winfried Rief
CNS & Neurological Disorders Drug Targets|November 24, 2016
How Immune-inflammatory Processes Link CNS and Psychiatric Disorders: Classification and Treatment ImplicationsGeorge Anderson, Michael Maes
CNS & Neurological Disorders Drug Targets|July 13, 2013
TRYCAT pathways link peripheral inflammation, nicotine, somatization and depression in the etiology and course of Parkinson's diseaseGeorge Anderson, Michael Maes
Molecular Neurobiology|October 3, 2013
Neurodegeneration in Parkinson's disease: interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuinsGeorge Anderson, Michael Maes
Pageof 73

Showing results (31-40 of 723) with videos related to

Sort By:
Pageof 73
CNS & Neurological Disorders Drug Targets|October 1, 2020
Biomarker Validation of a New Case Definition of Menstrual Cycle-Associated Syndrome (MCAS) Opinion PaperChutima Roomruangwong, Michael Maes
Current Pharmaceutical Design|December 31, 2014
Overlapping the Tryptophan Catabolite (TRYCAT) and Melatoninergic Pathways in Alzheimer's DiseaseMichael Maes, George Anderson
Frontiers in Psychiatry|July 5, 2021
False Dogmas in Schizophrenia Research: Toward the Reification of Pathway Phenotypes and Pathway ClassesMichael Maes, George Anderson
The International Journal of Neuropsychopharmacology|December 6, 2002
Effects of antidepressants on the production of cytokinesGunter Kenis, Michael Maes
Current Pharmaceutical Design|November 5, 2013
Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: treatment implicationsGeorge Anderson, Michael Maes
Journal of Affective Disorders|December 16, 2003
Partial posttraumatic stress disorder revisitedJacques Mylle, Michael Maes
Psychiatry Research|February 28, 2012
Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathwayMichael Maes, Winfried Rief
CNS & Neurological Disorders Drug Targets|November 24, 2016
How Immune-inflammatory Processes Link CNS and Psychiatric Disorders: Classification and Treatment ImplicationsGeorge Anderson, Michael Maes
CNS & Neurological Disorders Drug Targets|July 13, 2013
TRYCAT pathways link peripheral inflammation, nicotine, somatization and depression in the etiology and course of Parkinson's diseaseGeorge Anderson, Michael Maes
Molecular Neurobiology|October 3, 2013
Neurodegeneration in Parkinson's disease: interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuinsGeorge Anderson, Michael Maes
Pageof 73